What is Genetesis?
Genetesis is a pioneering healthcare technology firm dedicated to revolutionizing preventive cardiac care. At the core of its innovation is the CardioFlux platform, a sophisticated diagnostic system that utilizes magnetocardiography to detect functionally significant ischemia with unprecedented speed and accuracy. By providing a non-invasive alternative to traditional cardiac testing, the company addresses a critical gap in emergency department workflows and outpatient clinics.
The firm's market position is defined by its commitment to improving patient outcomes while simultaneously reducing hospital wait times and operational inefficiencies. By targeting the intersection of advanced physics and clinical cardiology, Genetesis provides healthcare professionals with actionable data, effectively setting a new standard for cardiac imaging and diagnostic efficiency in the modern medical environment.
How much funding has Genetesis raised?
Genetesis has raised a total of $35.9M across 5 funding rounds:
Angel/Seed
$1.2M
Series A
$7.5M
Series B
$9.2M
Debt
$508K
Series C
$17.5M
Angel/Seed (2016): $1.2M with participation from CincyTech and LOUD Capital
Series A (2018): $7.5M, investors not publicly disclosed
Series B (2020): $9.2M supported by TDK Ventures
Debt (2021): $508K featuring PPP
Series C (2022): $17.5M backed by CincyTech, Mithril Capital Management, Ohio Innovation Fund, JobsOhio, and Cercano Management
Key Investors in Genetesis
CincyTech
CincyTech is a public-private seed-stage investor based in Ohio that specializes in life sciences, digital health, and enterprise software applications.
Mithril Capital Management
Mithril Capital is a long-term venture capital firm that partners with teams leveraging technology to transform industries ripe for disruption.
Ohio Innovation Fund
The Ohio Innovation Fund is a venture firm focused on supporting disruptive startups in medtech, AI, and cybersecurity through strategic guidance and capital.
What's next for Genetesis?
With the successful closure of this major strategic investment, Genetesis is poised to enter a phase of aggressive commercial expansion and product refinement. The company's strategic roadmap focuses on deepening its footprint in the cardiac diagnostic market, likely through enhanced clinical validation studies and broader integration into hospital health systems. As the firm scales, the focus will remain on optimizing the CardioFlux Membership program to ensure widespread adoption among healthcare providers.
Furthermore, the infusion of capital will likely support the development of next-generation diagnostic features, reinforcing the company's competitive advantage in the medtech space. By maintaining a focus on both clinical efficacy and operational scalability, Genetesis is strategically aligned to capture significant market share, ultimately driving long-term value for its stakeholders and improving the standard of care for patients suffering from cardiac-related chest pain.
